274 related articles for article (PubMed ID: 24486595)
1. Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.
Kaneko N; Mitsuoka K; Amino N; Yamanaka K; Kita A; Mori M; Miyoshi S; Kuromitsu S
Clin Cancer Res; 2014 Apr; 20(7):1814-22. PubMed ID: 24486595
[TBL] [Abstract][Full Text] [Related]
2. Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab.
Kita A; Mitsuoka K; Kaneko N; Nakata M; Yamanaka K; Jitsuoka M; Miyoshi S; Noda A; Mori M; Nakahara T; Sasamata M
J Pharmacol Exp Ther; 2012 Oct; 343(1):178-83. PubMed ID: 22787117
[TBL] [Abstract][Full Text] [Related]
3. Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma.
Kaneko N; Kita A; Yamanaka K; Mori M
Leuk Res; 2013 Sep; 37(9):1156-61. PubMed ID: 23746965
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
[TBL] [Abstract][Full Text] [Related]
5. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells.
Liang H; Zhang L; Xu R; Ju XL
Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2909-15. PubMed ID: 24254560
[TBL] [Abstract][Full Text] [Related]
6. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
Nakahara T; Yamanaka K; Hatakeyama S; Kita A; Takeuchi M; Kinoyama I; Matsuhisa A; Nakano K; Shishido T; Koutoku H; Sasamata M
Anticancer Drugs; 2011 Jun; 22(5):454-62. PubMed ID: 21389848
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
[TBL] [Abstract][Full Text] [Related]
8. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.
Vacirca JL; Acs PI; Tabbara IA; Rosen PJ; Lee P; Lynam E
Ann Hematol; 2014 Mar; 93(3):403-9. PubMed ID: 23955074
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells.
Kaneko N; Yamanaka K; Kita A; Tabata K; Akabane T; Mori M
Biol Pharm Bull; 2013; 36(12):1921-7. PubMed ID: 24432379
[TBL] [Abstract][Full Text] [Related]
10. A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma.
Papadopoulos KP; Lopez-Jimenez J; Smith SE; Steinberg J; Keating A; Sasse C; Jie F; Thyss A
Leuk Lymphoma; 2016 Aug; 57(8):1848-55. PubMed ID: 26857688
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma.
Cheson BD; Bartlett NL; Vose JM; Lopez-Hernandez A; Seiz AL; Keating AT; Shamsili S; Papadopoulos KP
Cancer; 2012 Jun; 118(12):3128-34. PubMed ID: 22006123
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.
Tateishi U; Tatsumi M; Terauchi T; Ando K; Niitsu N; Kim WS; Suh C; Ogura M; Tobinai K
Cancer Sci; 2015 Feb; 106(2):186-93. PubMed ID: 25495273
[TBL] [Abstract][Full Text] [Related]
13. Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.
Chen J; Pise-Masison CA; Shih JH; Morris JC; Janik JE; Conlon KC; Keating A; Waldmann TA
Blood; 2013 Mar; 121(11):2029-37. PubMed ID: 23321252
[TBL] [Abstract][Full Text] [Related]
14. YM155 inhibits tumor growth and enhances chemosensitivity to cisplatin in osteosarcoma.
Gao JZ; Chen FH; Wang L; Wei H; Meng SL
Eur Rev Med Pharmacol Sci; 2015; 19(11):2062-9. PubMed ID: 26125270
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma.
Kita A; Nakahara T; Yamanaka K; Nakano K; Nakata M; Mori M; Kaneko N; Koutoku H; Izumisawa N; Sasamata M
Leuk Res; 2011 Jun; 35(6):787-92. PubMed ID: 21237508
[TBL] [Abstract][Full Text] [Related]
16. Survivin selective inhibitor YM155 promotes cisplatin‑induced apoptosis in embryonal rhabdomyosarcoma.
Ueno T; Uehara S; Nakahata K; Okuyama H
Int J Oncol; 2016 May; 48(5):1847-54. PubMed ID: 26983495
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS.
Minoda M; Kawamoto T; Ueha T; Kamata E; Morishita M; Harada R; Toda M; Onishi Y; Hara H; Kurosaka M; Akisue T
Int J Oncol; 2015 Sep; 47(3):891-9. PubMed ID: 26166250
[TBL] [Abstract][Full Text] [Related]
18. Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma.
Zhang L; Zhang W; Wang YF; Liu B; Zhang WF; Zhao YF; Kulkarni AB; Sun ZJ
Cell Death Dis; 2015 May; 6(5):e1771. PubMed ID: 26018732
[TBL] [Abstract][Full Text] [Related]
19. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo.
Ackler S; Mitten MJ; Chen J; Clarin J; Foster K; Jin S; Phillips DC; Schlessinger S; Wang B; Leverson JD; Boghaert ER
Br J Pharmacol; 2012 Oct; 167(4):881-91. PubMed ID: 22624727
[TBL] [Abstract][Full Text] [Related]
20. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]